Stanley-Laman Group’s Teva Pharmaceuticals TEVA Stock Holding History

Stanley-Laman Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-14,000	Closed	-$749K	–	332
2016 Q1	$749K	Hold	14,000	–	–	0.14%	144
2015 Q4	$919K	Hold	14,000	–	–	0.16%	151
2015 Q3	$790K	Hold	14,000	–	–	0.16%	146
2015 Q2	$827K	Hold	14,000	–	–	0.15%	158
2015 Q1	$872K	Hold	14,000	–	–	0.16%	152
2014 Q4	$805K	Hold	14,000	–	–	0.15%	151
2014 Q3	$753K	Hold	14,000	–	–	0.15%	144
2014 Q2	$734K	Sell	14,000 -500	-3%	-$25.6K	0.13%	154
2014 Q1	$766K	Buy	+14,500	New	+$670K	0.13%	166

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Stanley-Laman Group's TEVA Position: Q2 2016 in Review

Stanley-Laman Group sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 14,000 shares — an estimated $749K sold.

Stanley-Laman Group first reported a position in TEVA in Q1 2014 and held it in 9 quarters. The position peaked at $919K in Q4 2015. 812 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

Stanley-Laman Group reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Stanley-Laman Group sold 14,000 Teva Pharmaceuticals shares in Q2 2016, an estimated $749K.
Stanley-Laman Group first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 9 quarters.
Stanley-Laman Group's Teva Pharmaceuticals position peaked at $919K in Q4 2015.
812 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Stanley-Laman Group's 13F filing for Q2 2016, filed 4 Aug 2016.